On January 1, 2026, CMS fundamentally restructured how Medicare pays for skin substitutes. If your dermatology practice applies cellular and tissue-based products (CTPs), this is the biggest billing change you've faced in years — and the financial impact is massive.
Medicare Part B spending on CTPs exploded from $252 million in 2019 to over $10 billion in 2024. CMS responded with sweeping changes that affect reimbursement rates, product eligibility, waste billing, and prior authorization requirements. Here's exactly what changed and what your practice needs to do.
in Medicare spending
by Medicare
per sq cm
prior auth
What CMS Changed: The Three Big Shifts
1. Reclassification from Drugs to Supplies
CMS reclassified most skin substitutes (Section 361 HCT/Ps) from drugs and biologicals to "incident-to" medical supplies. This is not a minor category tweak — it fundamentally changes the payment methodology, eliminating the ASP + 6% pricing model that generated high margins for many practices.
2. Flat National Rate of $127.28 per Square Centimeter
All non-BLA skin substitutes are now reimbursed at a single flat rate: $127.28 per square centimeter. This is the volume-weighted average payment amount across all 361 HCT/Ps. The only exception: products licensed as biologicals under Section 351 of the Public Health Service Act (BLA products) retain ASP-based pricing.
3. 158 Products Delisted
Medicare determined that 158 CTP products lacked sufficient clinical data to support coverage. These products are no longer reimbursable. Only 18 products qualified for the "Covered" list with BLA biological status. Billing for a delisted product will result in an automatic denial.
If your practice is still billing for any of the 158 delisted products, you will receive automatic denials. Continued billing after denial could trigger fraud flags. Verify every CTP product in your formulary against the current CMS covered list immediately.
Before vs. After: Reimbursement Comparison
| Factor | Before 2026 | After Jan 1, 2026 |
|---|---|---|
| Classification | Drugs / Biologicals | Incident-to medical supplies |
| Pricing model | ASP + 6% (product-specific) | Flat rate: $127.28/sq cm |
| Covered products | Hundreds | 18 BLA + reduced non-BLA list |
| Waste billing | JW/JZ modifiers allowed | Zero-waste policy — no waste billing |
| Prior authorization | Not required | Required in 6 states (WISeR model) |
| Q-code requirements | Product-specific Q-codes | Product-specific Q-codes (unchanged) |
The Zero-Waste Policy: No More JW/JZ Modifiers
Under the 2026 rules, Medicare will not reimburse for discarded skin substitute product. Period. This is the "zero-waste" policy:
- Modifiers JW and JZ are no longer applicable for Section 361 HCT/Ps
- You can only bill for the exact amount applied to the patient
- Billing for waste constitutes a false claim under the new classification
- This applies to all non-BLA CTPs effective January 1, 2026
If you open a 5x5 cm sheet but only use 4x4 cm on the wound, you bill for 16 sq cm — not 25 sq cm. The remaining product is your practice's cost. This makes accurate wound measurement and product selection more financially critical than ever.
Prior Authorization: The WISeR Model (6 States)
CMS launched the Wasteful and Inappropriate Service Reduction (WISeR) model on January 1, 2026, introducing prior authorization requirements for skin substitutes in Medicare fee-for-service. The model is currently active in six states:
| State | Status | Effective |
|---|---|---|
| Arizona | Active | Jan 1, 2026 |
| New Jersey | Active | Jan 1, 2026 |
| Ohio | Active | Jan 1, 2026 |
| Oklahoma | Active | Jan 1, 2026 |
| Texas | Active | Jan 1, 2026 |
| Washington | Active | Jan 1, 2026 |
If your practice is in one of these states, you must obtain prior authorization before applying any skin substitute product on a Medicare patient. Claims submitted without prior auth will be denied automatically.
What Your Practice Should Do Right Now
- Audit your CTP formulary — Cross-reference every product you stock against the current CMS covered list. Remove any of the 158 delisted products from your inventory and billing workflows.
- Update wound measurement protocols — Under zero-waste, accurate measurement directly impacts revenue. Implement standardized measurement documentation for every CTP application.
- Recalculate product margins — At $127.28/sq cm flat rate, some products that were profitable under ASP + 6% are now margin-negative. Evaluate whether each product in your formulary is still financially viable.
- Build prior auth workflows (6 states) — If you're in AZ, NJ, OH, OK, TX, or WA, establish a pre-application prior auth process with designated staff and documented turnaround times.
- Train staff on new billing rules — Ensure every biller and coder understands: no waste billing, flat rate pricing, product eligibility verification, and Q-code documentation requirements.
- Monitor LCD status — CMS withdrew the new LCDs for skin substitutes that were scheduled for January 1. The situation remains fluid. Subscribe to MAC notifications for your jurisdiction.
Key Takeaways
- Most skin substitutes reclassified from drugs to incident-to supplies — ASP + 6% is gone
- New flat rate: $127.28 per square centimeter for all non-BLA CTPs
- 158 products delisted entirely — verify your formulary now
- Zero-waste policy: no JW/JZ modifiers, bill only what you apply
- Prior auth required in 6 states under the WISeR model
- Accurate wound measurement is now directly tied to revenue
- LCD status is fluid — monitor CMS and MAC communications closely